View in EDS HTML Full Text PDF Full Text

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.

Saved in:
Bibliographic Details
Title: Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.
Authors: Jaramillo, Sonia1 (AUTHOR) Sonia.jaramillosegura@med.uni-heidelberg.de, Le Cornet, Lucian2 (AUTHOR), Kratzmann, Markus2 (AUTHOR), Krisam, Johannes3 (AUTHOR), Görner, Martin4 (AUTHOR), Hänel, Mathias5 (AUTHOR), Röllig, Christoph6 (AUTHOR), Wass, Maxi7 (AUTHOR), Scholl, Sebastian8 (AUTHOR), Ringhoffer, Mark9 (AUTHOR), Reichart, Alexander10 (AUTHOR), Steffen, Björn11 (AUTHOR), Kayser, Sabine12 (AUTHOR), Mikesch, Jan-Henrik13 (AUTHOR), Schaefer-Eckart, Kerstin14 (AUTHOR), Schubert, Jörg15 (AUTHOR), Geer, Thomas16 (AUTHOR), Martin, Sonja17 (AUTHOR), Kieser, Meinhard17 (AUTHOR), Sauer, Tim1 (AUTHOR)
Source: Trials. 9/15/2023, Vol. 24 Issue 1, p1-15. 15p. 3 Charts, 1 Graph.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:17456215
DOI:10.1186/s13063-023-07421-x